Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gliatech and Chugai sign licensing agreement:

This article was originally published in Clinica

Executive Summary

Chugai Pharmaceutical is to market Gliatech's Adcon-L and Adcon-T/N anti-adhesion barrier gels in Japan under an exclusive licence agreement announced by the two companies on January 13th. Chugai will fund and conduct all clinical trials and regulatory filings required to obtain marketing approval for the products in Japan. Adcon-L and Adcon-T/N are the first in a line of products being developed by Gliatech (US) for the inhibition of post-surgical scarring and adhesions. Both products are already on the market in Europe, and are in clinical trials in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel